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Oropharyngeal candidiasis (OPC) that is refractory to therapy
with fluconazole has been increasingly reported in HIV-
infected patients after long-term use of fluconazole [1].
Recently, a patient was reported in whom fluconazole-refrac-
tory mucosal candidiasis resolved after the initiation of treat-
ment with an antiretroviral agent combined with a protease
inhibitor [2]. It was argued that improving immune function
was responsible for this effect, but information about the Can-
dida strains was not given. In this report, we describe a patient
who suffered from fluconazole-refractory oral and esophageal
candidiasis (OC) but resolved this disease after a change in
antifungal therapy as well as initiation of highly active anti-
retroviral therapy (HAART), together with clearance of the
fluconazole-resistant C. albicans strain.
A 37-year-old homosexual man with HIV infection diag-
nosed in 1993 presented in March 1996 with a gastric lym-
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phoma and OC. The CD4 count was 2/mL, and the HIV load
was 32  103 copies RNA/mL. He had a history of recurrent
OPC since 1994 and had received daily treatment with flu-
conazole 200–400 mg/day for the past 2 years. The Epstein–
Barr virus-associated lymphoma in the stomach was treated
with chemotherapy and resolved in May 1996. During this
period, OPC and OC persisted despite administration of flu-
conazole (200–400 mg/day) and amphotericin B oral sus-
pension (12 mL/day). In November 1996, intravenous therapy
with Ambisome (5 mg/kg/day) was given and candidiasis
resolved temporarily, but reoccurred rapidly under secondary
prophylaxis with Ambisome (5 mg/kg/day) given once-weekly
in January 1997. Antiretroviral therapy was changed from single
therapy with saquinavir in November 1996 to triple therapy
(HAART) with zidovudine (250 mg twice-daily), lamivudine
(150 mg twice-daily) and saquinavir (600 mg thrice-daily). Due
Concise Communications 221
T
ab
le
1
Fl
u
co
n
az
o
le
su
sc
ep
ti
b
ili
ty
an
d
D
N
A
su
b
ty
p
e
ch
ar
ac
te
ri
za
ti
o
n
o
f
C
.a
lb
ic
an
s
is
o
la
te
s
fr
o
m
a
p
at
ie
n
t
w
it
h
fl
u
co
n
az
o
le
-r
ef
ra
ct
o
ry
ca
n
d
id
ia
si
s
D
ay
o
f
sa
m
p
le
A
n
ti
fu
n
g
al
th
er
ap
y
Lo
ca
ti
o
n
M
IC
Fl
u
co
n
az
o
le
(m
g
/L
)
M
IC
It
ra
co
n
az
o
le
(m
g
/L
)
C
FU
/m
L
D
N
A
su
b
ty
p
e
A
P
I3
2I
D
co
d
e
1
19
A
p
ri
l1
99
6
Fl
u
co
n
az
o
le
20
0
m
g
O
ra
l
25
25
10
3
A
71
47
34
00
15
2
9
M
ay
19
96
Fl
u
co
n
az
o
le
20
0
m
g
O
ra
l
1.
56
1.
56
10
3
B
1
71
47
34
00
15
E
so
p
h
ag
ea
l
25
25
+
A
71
42
30
00
15
S
to
m
ac
h
25
25
+
A
71
43
34
00
15
3
4
Ju
ly
19
96
Fl
u
co
n
az
o
le
20
0
m
g
E
so
p
h
ag
ea
l
25
25
+
A
71
47
34
00
15
4
17
Ju
ly
19
96
Fl
u
co
n
az
o
le
20
0
m
g
O
ra
l
1.
56
1.
56
10
4
B
1
71
47
34
00
15
5
23
Ju
ly
19
96
Fl
u
co
n
az
o
le
20
0
m
g
E
so
p
h
ag
ea
l
25
25
+
A
71
47
34
00
15
6
16
A
u
g
u
st
19
96
Fl
u
co
n
az
o
le
20
0
m
g
O
ra
l
1.
56
1.
56
10
3
B
1
71
47
34
00
15
E
so
p
h
ag
ea
l
10
0
25
+
A
71
43
34
00
15
S
to
m
ac
h
25
25
+
A
71
47
34
00
15
7
14
N
o
ve
m
b
er
19
96
Fl
u
co
n
az
o
le
20
0
m
g
O
ra
l
0.
09
0.
09
10
3
B
2
71
47
34
00
15
E
so
p
h
ag
ea
l
0.
09
0.
09
+
B
2
71
47
34
00
15
8
29
N
o
ve
m
b
er
19
96
A
ft
er
A
m
b
is
o
m
e
5
m
g
/k
g

7
d
ay
s
O
ra
l
1.
56
1.
56
10
1
B
1
71
47
34
00
15
9
6
D
ec
em
b
er
19
96
A
ft
er
A
m
b
is
o
m
e
o
n
ce
w
ee
kl
y
O
ra
l
–
–
N
o
g
ro
w
th
–
10
13
D
ec
em
b
er
19
96
A
m
b
is
o
m
e
o
n
ce
w
ee
kl
y
O
ra
l
10
0
6.
25
10
1
A
71
47
34
00
15
11
3
Ja
n
u
ar
y
19
97
A
m
b
is
o
m
e
o
n
ce
w
ee
kl
y
O
ra
l
6.
25
1.
56
10
4
B
1
71
47
34
00
15
E
so
p
h
ag
ea
l
6.
25
0.
39
+
B
1
71
47
34
00
15
S
to
m
ac
h
6.
25
0.
39
+
B
1
71
47
34
00
15
12
7
Fe
b
ru
ar
y
19
97
A
ft
er
A
m
b
is
o
m
e
O
ra
l
6.
25
1.
56
10
2
B
1
71
47
34
00
15
S
ta
rt
it
ra
co
n
az
o
le
20
0
m
g
tw
ic
e-
d
ai
ly
E
so
p
h
ag
ea
l
25
25
+
A
71
47
34
00
15
S
to
m
ac
h
6.
25
1.
56
+
B
1
71
47
34
00
15
13
7
M
ar
ch
19
97
A
ft
er
it
ra
co
n
az
o
le
O
ra
l
–
–
N
o
g
ro
w
th
–
14
6
A
u
g
u
st
19
97
B
ef
o
re
it
ra
co
n
az
o
le
O
ra
l
1.
56
0.
09
10
5
B
1
71
47
34
00
15
15
27
A
u
g
u
st
19
97
A
ft
er
it
ra
co
n
az
o
le
O
ra
l
1.
56
0.
39
10
2
B
1
71
47
14
00
15
E
so
p
h
ag
ea
l
–
–
N
o
g
ro
w
th
–
S
to
m
ac
h
–
–
N
o
g
ro
w
th
–
16
26
M
ay
19
98
N
o
th
er
ap
y
O
ra
l
1.
56
0.
09
10
1
B
1
71
47
34
00
15
E
so
p
h
ag
ea
l
–
–
N
o
g
ro
w
th
–
S
to
m
ac
h
–
–
N
o
g
ro
w
th
–
17
12
Ju
n
e
19
98
B
ef
o
re
it
ra
co
n
az
o
le
O
ra
l
1.
56
0.
39
10
1
B
1
71
47
34
00
15
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 218–225
222 Clinical Microbiology and Infection, Volume 6 Number 4, April 2000
Figure 1(a) Profiles of AP-PCR fingerprints are presented for 11 iso-
lates of C. albicans from biopsies obtained from the esophagus and
stomach of a single patient. Esophagus: lane 1, 9 May 1996; lane 3,
4 July 1996; lane 4, 23 July 1996; lane 6, 16 August 1996; lane 7, 14
November 1996; lane 8, 3 January 1997; lane 10, 7 February 1997).
Stomach: lane 2, 9 May 1996; lane 5, 16 August 1996; lane 9, 3 March
1997; lane 11, 7 February 1997. Samples were amplified by the
primer RP02 [5]. Genotypes presented in lanes 1–6 and 10 (genotype
A) were considered to be identical, as well as those in lanes 8–9 and
11 (genotype B1). The genotype in lane 7 was similar to genotype
B1 but differed in one band and was considered to be subtype B2.
The molecular size marker DNA VI (Boehringer-Ingelheim,
Ingelheim, Germany) is presented to the left of the gel (M). kb,
kilobase. (b): Profiles of AP-PCR fingerprints are presented for 13
isolates of C. albicans from oral mouthwashes obtained from a single
patient: lane 1, 19 April 1996; lane 2, 9 May 1996; lane 3, 17 July
1996; lane 4, 16 August 1996; lane 5, 14 November 1996; lane 6, 29
November 1996; lane 7, 13 December 1996; lane 8, 3 January 1997;
lane 9, 7 February 1997; lane 10, 6 August 1997; lane 11, 27 August
1997; lane 12, 26 May 1997; lane 13, 12 June 1998. Samples were
amplified by the primer RP02 [5]. Genotypes presented in lanes 1
and 7 were considered to be identical, as well as those in lanes 2–4,
6 and 8–13. The genotype in lane 5 was similar to genotype B1 but
differed in one band and was considered to be subtype B2. kb,
kilobase.
to the reappearance of OC in January 1997, Ambisome was
stopped and itraconazole (cyclodextrin solution 200 mg twice-
daily) was given. Candidiasis resolved and the patient stopped
taking itraconazole in April 1997 When the patient was seen
again in August 1997, there were signs of recurrent OPC.
Candidiasis responded well to 2 weeks of therapy with itra-
conazole (200 mg twice-daily), with clearance of OPC and
OC. The CD4 count was 75/mL, the HIV load was 43  103
copies RNA/mL, and the patient reported wellbeing. Myco-
logically, no growth of yeasts from the esophagus could be
documented. The patient was seen again in May 1998, and was
still in overall good condition without clinical or endoscopic
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signs of OPC/OC. Again, no growth of yeasts from the eso-
phagus or stomach could be documented. The CD4 count was
6/mL, the HIV virus load was 88  103 copies RNA/mL, and
antiretroviral therapy was changed to stavudine, didanosine
(ddI) and nevirapine. At the final visit in June 1998, the patient
presented with another recurrence of OPC, which was again
effectively treated with itraconazole cyclodextrin solution.
All samples (mouthwashes and biopsies) were plated on
CHROMagar (Fa. Mast Diagnostika, Reinfeld, Germany), and
the plates were incubated for 48 h at 30 °C. Mycologic identi-
fication was performed using methods such as growth on
CHROMagar, the germ tube test and the API32ID system.
From samplings 1–12, one individual colony, and from sam-
plings 13–17, five individual colonies of each C. albicans isolate
were picked from the primary culture plate and used for anti-
fungal susceptibility testing and DNA subtyping. In vitro sus-
ceptibility testing with fluconazole and itraconazole was
performed on all C. albicans isolates as described earlier [3].
DNA subtyping of all C. albicans isolates was performed using
arbitrarily primed PCR (AP-PCR) by use of primer RP02 (5?-
GCGATCCCCA-3?) as well as southern blot hybridization
using a C. albicans-specific (CARE-2) probe of EcoRI-digested
DNA [4,5].
MICs, API32ID codes and DNA subtypes from Candida
isolates obtained from various locations during the observation
period of 2 years are presented in Table 1. Isolates from
different episodes and different anatomic locations shared two
genotypes (A + B with two subtypes B1 + B2) from episodes
1–12 and only one genotype in episodes 13–17 (Figure 1).
PCR and ‘CARE-2’ typing produced highly comparable
results. Therefore, only results for AP-PCR are shown.
It has been recently claimed that mucosal candidiasis refrac-
tory to fluconazole may resolve not primarily as a result of
changing the antifungal therapy to a different agent, but because
of the introduction of antiretroviral triple therapy, which is
currently the standard therapy for HIV infection [2,6]. This
effect has also been observed in a larger cohort of patients with
fluconazole-sensitive OPC [7,8]. The decreasing incidence of
several opportunistic infections has been primarily related to
the improvement of the immune system following HAART
and not to an antimicrobial effect directed against various viral,
bacterial or fungal pathogens. Itraconazole solution has become
an attractive alternative for fluconazole-refractory candidiasis,
with temporary clinical response in up to 65% of patients [9,10].
However, even if patients respond to alternative antifungal
agents such as itraconazole, it has not been documented so
far that fluconazole-refractory candidiasis may resolve together
with the elimination of the resistant C. albicans strain or even
replacement by a fluconazole-sensitive strain. In the patient
presented here, the fluconazole-resistant C. albicans strain could
be detected in samples from mouthwashes as well as from
esophageal and stomach biopsies. It is not known whether C.
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albicans strains adhere better to epithelial cells of the oral cavity
or the esophagus, but it is accepted that esophageal candidiasis
represents a form of invasive candidiasis which requires higher
dosages of antifungal drugs compared to OPC [11]. In this
patient, replacement of a fluconazole-resistant C. albicans strain
by a genetically different fluconazole-sensitive strain was
observed; this finally caused further recurrences of OPC, which
responded well to intermittent therapy with itraconazole solu-
tion. However, it is unclear whether the disappearance of the
resistant genotype is due to the temporary increase of the CD4
cell count or because of therapy with itraconazole despite high-
level resistance to azoles in vitro.
It may be concluded that serial DNA typing of C. albicans
strains, together with antifungal susceptibility testing, may help
us to monitor the susceptibility of clinical isolates to azole
therapy.
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Many Legionella species are found in the natural environment
and one of them, Legionella pneumophila, is responsible for more
than 90% of cases of Legionnaires’ disease [1]. Outbreaks of
community-acquired and nosocomial L. pneumophila infections
have been described [2,3].
The laboratory detection of the Legionella infection remains
difficult. The serological diagnosis, although fairly specific, has
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body to Legionella species or serogroups other than L. pneu-
mophila serogroup 1 [4]. The results are also highly influenced
by the kind of antigen (formolized or heated) used for the
diagnosis of seroconversion. In addition, serological diagnosis
can be difficult since the rise in antibody titres can be delayed.
The sensitivity of the direct fluorescence assay for the antigen
detection remains highly variable, from 30 to 80% [5]. The
detection of the L. pneumophila serogroup 1 urinary antigen
with commercially available enzyme immunoassay (EIA) kits
